Expert Says Olutasidenib Appears Safe as Monotherapy in Relapsed/Refractory IDH1-Mutant Gliomas

July 10, 2020

In an interview with Targeted Oncology, Macarena de la Fuente, MD, discussed the findings from a phase 1b/2 study of olutasidenib as treatment of patients with relapsed/refractory IDH1-mutated gliomas, either alone or in combination with azacitidine.

Trending News on Targeted Oncology, Week of July 10, 2020

July 10, 2020

Targeted Oncology reviews trending news online for the week of July 10, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

F-627 Induces Lasting Benefit as Treatment of Chemotherapy-Induced Neutropenia in Breast Cancer

July 10, 2020

Based on phase 3 findings, F-627 appears at least as efficacious and safe as pegfilgrastim, which is the current standard of care, demonstrating strong and durable benefit in patients with breast cancer.

Phase 3 Study Findings Show the Importance of T-DM1 in Early-Stage Breast Cancer

July 10, 2020

In an interview with Targeted Oncology, Julie R. Gralow, MD, discussed the findings from the KAITLIN study of T-DM1 in early-stage breast cancer.

Committee Helps Physician's Find Best Options for Patients Through NGS

July 10, 2020

Jennifer Marie Suga, MD, discusses how the results from next-generation sequencing tests are assessed to help physicians manage their patients in real-time.

Role of Targeted Therapies in Advanced Cholangiocarcinoma

July 10, 2020

Saeed Sadeghi, MD, comments on the utilization of FGFR2 inhibitors as treatment for advanced cholangiocarcinoma.

Bortezomib Consolidation or Maintenance Extends Survival With R-CHOP in MCL

July 09, 2020

The addition of bortezomib consolidation therapy or bortezomib maintenance to the immunochemotherapy regimen rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone improved progression-free survival in patients with mantle cell lymphoma in the post-transplant setting, according to a comparative analysis, CALGB/Alliance 5040 trial.

Evaluating the Role of EGFR Mutations in the Treatment of Advanced NSCLC

July 09, 2020

Balazs Halmos, MD, MS, discusses the role of EGFR mutations in patients with advanced non—small cell lung cancer.

Body Mass Index May Impact Docetaxel-Based Treatment Regimens in Breast Cancer

July 09, 2020

“By retrospectively analyzing data from the adjuvant BIG 2-98 trial, we demonstrated that overweight and obese patients treated with a docetaxel-based chemotherapy regimen presented with a worse disease-free and overall survival compared with average weight patients treated with the same chemotherapy regimen."

HEPANOVA Trial Update: Final Patient With HCC Enrolled to Receive TTFields/Sorafenib

July 09, 2020

The last patient with advanced hepatocellular carcinoma was enrolled on the phase 2 HEPANOVA trial, which is investigating the combination of Tumor Treating Fields and sorafenib. The combination showed safety and tolerability for patients in an interim analysis.